Corporate Officer

Direct Line: 0151 643 5380

Email: foirequests.nhswirralccg@nhs.net

Our Ref: ID 1108



NHS Wirral Clinical Commissioning Group Old Market House Hamilton Street Birkenhead Wirral CH41 5AL

Tel: 0151 651 0011

Re: Freedom of Information Request

Thank you for your request for information made under the Freedom of Information Act 2000 which was received into this office on 17th May 2018.

You Asked for:

Information regarding prescribing QIPP and rebate schemes as potentially used by your organisation.

A - For the Financial Year 2017/2018

<u>Could you please provide me with the details of any prescribing rebate schemes and QIPP/efficiency saving prescribing schemes active within your **CCG during the financial year 2017/18**?</u>

Please answer the questions below:

1. Primary Care Prescribing Rebate Schemes 2017/18

Name of Scheme	Drug(s) covered	Companies involved in the scheme

- 2. What was the total income for the CCG from rebates during 2017/18?
- 3. QIPP Prescribing Schemes 17/18

Name of Scheme	Drug(s) covered

B – For the Financial Year 2018/2019

Could you please provide me with the details of any prescribing rebate schemes and QIPP/efficiency saving prescribing schemes active within your CCG for the current financial year 2018-19 (as they currently stand)?

1 Current Primary Care Prescribing Rebate Schemes 18/19

Name of Scheme	Drug(s) covered	Companies involved in the scheme

2 Current QIPP Prescribing Schemes 18/19

Name of Scheme	Drug(s) covered

- 3. What is the current year 18/19 CCG QIPP/efficiency savings plan target?
- 4. What is the value of the prescribing element for the current year 18/19 CCG QIPP/efficiency savings plan target?

Our Response:

1. Primary Care Prescribing Rebate Schemes 2017/18

Name of scheme	Drug(s) covered	Companies involved
Alzain (pregabalin)	Alzain	Dr Reddys Laboratories (UK) Ltd
Clexane	Clexane	Sanofi
Ascensia	Contour Next (Reagent)_Strips	Ascensia Diabetes Care
Firmagon Degarelix	Firmagon	Ferring Pharmaceuticals Ltd
Gluco RX	Gluco Rx	GlucoRx Limited
Glucophage	Glucophage	Merck UK
Lantus	Lantus	Sanofi
Seretide	Seretide	Glaxosmithkline UK Limited
Sitagliptin	Januvia (sitagliptin)	Merck UK
Spiolto	Spiolto Respimat	Boehringer Ingelheim Ltd
Symbicourt	Symbicourt Turbohaler	AstraZenica UK Ltd
Glucomen	Glucomen/jet	Menarini Diagnostics Ltd

- 2. What was the total income for the CCG from rebates during 2017/18? £265,491
- 3. QIPP Prescribing Schemes 17/18

Name of Scheme	Drug(s) covered
	Pain, CNS, diabetes, GI, antibiotics, eye,specialist feeds, CV and respiratory
Cost improvement work	
Self care and homeopathy	
Clinical medication reviews Repeat ordering	Looking at the repeat ordering process.

B – For the Financial Year 2018/2019

1 Current Primary Care Prescribing Rebate Schemes 18/19

Name of scheme	Drug(s) covered	Companies involved
		Dr Reddys Laboratories (UK)
Alzain (pregabalin)	Alzain	Ltd
Clexane	Clexane	Sanofi
Ascensia	Contour Next (Reagent)_Strips	Ascensia Diabetes Care
Firmagon Degarelix	Firmagon	Ferring Pharmaceuticals Ltd
Gluco RX	Gluco Rx	GlucoRx Limited
Glucophage	Glucophage	Merck UK
Lantus	Lantus	Sanofi
Seretide	Seretide	Glaxosmithkline UK Limited
Sitagliptin	Januvia (sitagliptin)	Merck UK
Spiolto	Spiolto Respimat	Boehringer Ingelheim Ltd
Glucomen	Glucomen/jet	Menarini Diagnostics Ltd

2 Current QIPP Prescribing Schemes 18/19

Name of Scheme	Drug(s) covered
Long term conditions reviews	Drugs within the clinical areas of pain, diabetes, respiratory and cardiovascular
Deprescribing/waste	Polypharmacy (patients on 15 or more medicines), NHSE policies and national guidance, care homes and repeat prescribing systems
Safety & risk	Antibiotics, controlled drugs, STOMPLD, MHRA alerts, specials reviews, Pan Mersey engagement
Cost effective reviews	Cost improvement plan

- 3. What is the current year 18/19 CCG QIPP/efficiency savings plan target? £19.6 million
- 4. What is the value of the prescribing element for the current year 18/19 CCG QIPP/efficiency savings plan target? £4.3 million

We hope this information is useful, however if you require any further information please do not hesitate to contact a member of the Corporate Affairs Team (contact details at the top of this letter)

Yours sincerely

Re- Use of Information

Most of the information that we provide in response to Freedom of Information Act 2000 requests will be subject to copyright protection. In most cases the copyright will be owned by Wirral Clinical Commissioning Group. The copyright in other information may be owned by another person or organisation, as indicated on the information itself.

You are free to use any information supplied for your own non-commercial research or private study purposes. The information may also be used for any other purpose allowed by a limitation or exception in copyright law, such as news reporting. However, any other type of re-use, for example by publishing the information in analogue or digital form, including on the internet, will require the permission of the copyright owner.

For information where the copyright is owned by Wirral Clinical Commissioning Group please e-mail foirequests.nhswirralccg@nhs.net to request a reuse licence.

For information where the copyright is owned by another person or organisation you must apply to the copyright owner to obtain their permission.